Aim immunotech broadens patent portfolio with new netherlands utility patent covering ampligen® and other aim-developed dsrna products to include rugged dsrna for use in covid-19 treatment or prevention

Ocala, fla., jan. 09, 2023 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases — including covid-19, the disease caused by the sars-cov-2 virus— today announced that the netherlands patent office (octrooicentrum nederland) has granted a utility patent covering rugged dsrna, a double-stranded rna product related to ampligen® (rintatolimod), which claims cover, among other aspects, compositions and compositions for use in the prevention or treatment of covid-19. the new patent broadens aim's existing portfolio for covid-19 treatments to include rugged dsrna.
AIM Ratings Summary
AIM Quant Ranking